EGFR and non-small cell lung carcinoma: Meanwhile, we also observed similar results in NSCLC cells that express activating mutation-possessed EGFR, as knockdown of SHCBP1 remarkably suppressed tumor sphere formation capacity as well as activation of β-catenin signaling (Fig. 4f and Supplementary Fig. 4c).